Medpace Holdings, Inc. Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Medpace Holdings, Inc. (MEDP) reported Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $19.67 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2017-02-28
- Medpace Holdings, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2016 was $19.67M.
- Medpace Holdings, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2015 was -$37.65M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|
| 2016-12-31 | $19.67M 10-K · filed 2017-02-28 | |
| 2015-12-31 | -$37.65M 10-K · filed 2017-02-28 | |
| 2014-12-31 | $55.39M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |